Paragon Therapeutics moves migraine-focused Mentari Therapeutics public via reverse merger
read at Endpoints ↗DealNeutral
Paragon Therapeutics, a hub-and-spoke biotech company, is taking its migraine drug subsidiary Mentari Therapeutics public through a reverse merger.
The approach follows Paragon's prior use of reverse mergers to bring offshoots to market, giving Mentari access to capital without a traditional IPO.
By listing publicly, Mentari aims to advance its migraine pipeline while Paragon retains strategic control and benefits from the new public listing.
source
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “Another Paragon offshoot chooses reverse merger, this time for migraine drugs”
read at Endpoints ↗82 words · retrieved May 19
comments(0)
5-min edit window · permanent after that